| AMFAR | American Foundation for AIDS Research |
|---|---|
| ARC | accelerating rate calorimetry; acquired immunodeficiency syndrome-related complex; active renin conc... |
| ARE | active-resistive exercises; AIDS-related encephalitis |
| FACMTA | Federal Advisory Council on Medical Training Aids |
| NADR | National AIDS Demonstration Research; noradrenalin |
| vaccine, flu | The flu (influenza) vaccine is recommended for persons at high risk for serious complications from influenza infection, including everyone 65 or over; people with chronic diseases of the heart, lung or kidneys, diabetes, immunosuppression, or severe forms of anaemia; residents of nursing homes and other chronic-care facilities, children and teenagers taking aspirin therapy (and who may therefore be at risk for developing reye syndrome after an influenza infection), and those in close or frequent contact with anyone at high risk. Persons with an allergy to eggs should not receive influenza vaccine. (12 Dec 1998) |
|---|---|
| vaccine, influenza | See Vaccine, flu. Vaccination, dtap: like dpt, dtap protects from diphtheria, pertussis (whooping cough) and tetanus. Dtap is the same as dtp, except that it contains only acellular pertussis vaccine which is thought to cause fewer of the minor reactions associated with immunization and is also probably less likely to cause the more severe reactions occasionally seen following pertussis vaccination. Dtap is currently recommended only for the shots given at 18 months and 4-6 years of age. Vaccination, dt: dt (diphtheria and tetanus) vaccine does not protect from pertussis and is usually reserved for individuals who have had a significant adverse reaction to a dpt shot or who have a personal or family history of a seizure disorder or brain disease. (12 Dec 1998) |
| vaccine lymph | Vaccinia lymph, that collected from the vesicles of vaccinia infection, and used for active immunization against smallpox. (05 Mar 2000) |
| variola vaccine | <dermatology> The cutaneous and sometimes systemic reactions associated with vaccination with smallpox vaccine. (18 Nov 1997) |
| measles, mumps and rubella vaccine | A combination of live attenuated measles, mumps, and rubella viruses in an aqueous suspension; used for immunization against the respective diseases. (05 Mar 2000) |
| measles vaccine | A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunised with live measles vaccine and have no serum antibodies against measles. Children are usually immunised with measles-mumps-rubella combination vaccine. (12 Dec 1998) |
| measles virus vaccine | Vaccine containing live, attenuated strains of measles virus prepared in chick embryo cell culture. See: measles, mumps, and rubella vaccine. (05 Mar 2000) |
| Pasteur vaccine | An inactivated virus vaccine, used for preexposure immunization to persons at high risk of exposure, e.g., veterinarians, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. The official preparation is human diploid cell vaccine produced from rabies virus grown in cultures of human diploid embryo lung cells and inactivated with propriolactone. It has a much lower incidence of adverse reactions than the previously used duck embryo vaccine. (12 Dec 1998) |
| chickenpox vaccine | <pharmacology, virology> A live-varicella virus vaccine. Limited clinical trials suggest the immunity lasts for at least six years. The only significant adverse reaction detected in clinical studies was pain and redness at the injection site. Children (or adults) with a history for an anaphylactoid reaction to neomycin or gelatin or the presence of any febrile illness, should not be given the vaccine. Pregnant women and those who are immunocompromised should also not receive the vaccine. It is furthermore recommended that pregnancy be avoided for 3 months following vaccination. In trials involving 9,000 children, 80% were protected and 20% reported mild cases. It is recommended for children between the ages of 12 months and 13 years. (12 Dec 1998) |
| rickettsia vaccine | Attenuated See: typhus vaccine. (05 Mar 2000) |
| pertussis vaccine | A suspension of killed bordetella pertussis organisms, used for immunization against pertussis (whooping cough). It is generally used in a mixture with diphtheria and tetanus toxoids (dtp). There is an acellular pertussis vaccine prepared from the purified antigenic components of bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (12 Dec 1998) |
| cholera vaccine | A killed bacteria vaccine containing equal portions of the inaba and ogawa strains of vibrio cholerae, used for immunization against cholera. It enhances protection in adults for about six months, but does not reduce faecal shedding of bacteria or reduce disease transmission. Other cholera vaccines are under development. (12 Dec 1998) |
| Rocky Mountain spotted fever vaccine | Suspension of inactivated Rickettsia rickettsii prepared by growing the rickettsiae in the embryonate yolk sac of fowl eggs. (05 Mar 2000) |
| rubella vaccine | A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunised and do not have serum antibodies to rubella. Children are usually immunised with measles-mumps-rubella combination vaccine. (12 Dec 1998) |
| rubella virus vaccine | A live virus vaccine prepared from duck embryo or human diploid cell culture infected with rubella virus; administered as a single subcutaneous injection. See: measles, mumps, and rubella vaccine. (05 Mar 2000) |